Pyrotinib for HER2-positive advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether taking pyrotinib continuously or intermittently can help people with HER2-positive advanced breast cancer that has spread. It is for those who have already received prior treatment for their advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced or locally advanced breast cancer that cannot be removed by surgery.
- Your cancer is HER2-positive (confirmed by a biopsy at least once).
- You have already received treatment for advanced disease and your doctor thinks pyrotinib could help.
- You have at least one tumor that can be measured on scans or have cancer only in your bones (with some bone damage).
- You are in good general health (ECOG score 0 or 1) with normal organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with advanced breast cancer that has a protein called HER2 to see how well pyrotinib (a targeted drug) works when used in routine clinical practice. You'd be tracked over time to understand how this treatment affects your cancer and quality of life.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
This Phase 3 trial tests whether continuing or pausing the anti-HER2 medicine pyrotinib after surgery can lower the chance that invasive HER2-positive breast cancer comes back. It may help people who have recently finished trastuzumab or T-DM1 and are well enough to take tablets.
This trial tests a combination of two targeted drugs, GQ1001 and pyrotinib, for people with HER2-positive breast cancer that has spread to other parts of the body and has not responded to at least one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This study tests a targeted therapy called pyrotinib for people with advanced or metastatic HER2-positive breast cancer. It aims to see how well the drug works in a real-world setting, helping guide treatment for this specific type of cancer.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.